Patrick C Dolder1,2, Matthias E Liechti1, Katharina M Rentsch1. 1. Laboratory Medicine, University Hospital and University of Basel, Basel, Switzerland. 2. Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
Abstract
BACKGROUND:Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of this study was to develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of LSD, iso-LSD, 2-oxo-3-hydroxy LSD (O-H-LSD), and nor-LSD in plasma samples from 24 healthy subjects after controlled administration of 100 μg LSD in a clinical trial. In addition, metabolites that have been recently described in in vitro studies, including lysergic acid monoethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD, should be identified. METHODS: Separation of LSD and its metabolites was achieved on a reversed phase chromatography column after turbulent-flow online extraction. For the identification and quantification, a triple-stage quadrupole LC-MS/MS instrument was used. RESULTS: The validation data showed slight matrix effects for LSD, iso-LSD, O-H-LSD, or nor-LSD. Mean intraday and interday accuracy and precision were 105%/4.81% and 105%/4.35% for LSD, 98.7%/5.75% and 99.4%/7.21% for iso-LSD, 106%/4.54% and 99.4%/7.21% for O-H-LSD, and 107%/5.82% and 102%/5.88% for nor-LSD, respectively. The limit of quantification was 0.05 ng/mL for LSD, iso-LSD, and nor-LSD and 0.1 ng/mL for O-H-LSD. The limit of detection was 0.01 ng/mL for all compounds. CONCLUSION: The method described herein was accurate, precise, and the calibration range within the range of expected plasma concentrations. LSD was quantified in the plasma samples of the 24 subjects of the clinical trial, whereas iso-LSD, O-H-LSD, nor-LSD, LAE, LEO, 13/14-hydroxy-LSD, and 2-oxo-LSD could only sporadically be detected but were too low for quantification.
RCT Entities:
BACKGROUND:Lysergic acid diethylamide (LSD) is a widely used recreational drug. The aim of this study was to develop and validate a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantification of LSD, iso-LSD, 2-oxo-3-hydroxy LSD (O-H-LSD), and nor-LSD in plasma samples from 24 healthy subjects after controlled administration of 100 μg LSD in a clinical trial. In addition, metabolites that have been recently described in in vitro studies, including lysergic acid monoethylamide (LAE), lysergic acid ethyl-2-hydroxyethylamide (LEO), 2-oxo-LSD, trioxylated-LSD, and 13/14-hydroxy-LSD, should be identified. METHODS: Separation of LSD and its metabolites was achieved on a reversed phase chromatography column after turbulent-flow online extraction. For the identification and quantification, a triple-stage quadrupole LC-MS/MS instrument was used. RESULTS: The validation data showed slight matrix effects for LSD, iso-LSD, O-H-LSD, or nor-LSD. Mean intraday and interday accuracy and precision were 105%/4.81% and 105%/4.35% for LSD, 98.7%/5.75% and 99.4%/7.21% for iso-LSD, 106%/4.54% and 99.4%/7.21% for O-H-LSD, and 107%/5.82% and 102%/5.88% for nor-LSD, respectively. The limit of quantification was 0.05 ng/mL for LSD, iso-LSD, and nor-LSD and 0.1 ng/mL for O-H-LSD. The limit of detection was 0.01 ng/mL for all compounds. CONCLUSION: The method described herein was accurate, precise, and the calibration range within the range of expected plasma concentrations. LSD was quantified in the plasma samples of the 24 subjects of the clinical trial, whereas iso-LSD, O-H-LSD, nor-LSD, LAE, LEO, 13/14-hydroxy-LSD, and 2-oxo-LSD could only sporadically be detected but were too low for quantification.
Authors: Enzo Tagliazucchi; Leor Roseman; Mendel Kaelen; Csaba Orban; Suresh D Muthukumaraswamy; Kevin Murphy; Helmut Laufs; Robert Leech; John McGonigle; Nicolas Crossley; Edward Bullmore; Tim Williams; Mark Bolstridge; Amanda Feilding; David J Nutt; Robin Carhart-Harris Journal: Curr Biol Date: 2016-04-13 Impact factor: 10.834
Authors: Mendel Kaelen; Leor Roseman; Joshua Kahan; Andre Santos-Ribeiro; Csaba Orban; Romy Lorenz; Frederick S Barrett; Mark Bolstridge; Tim Williams; Luke Williams; Matthew B Wall; Amanda Feilding; Suresh Muthukumaraswamy; David J Nutt; Robin Carhart-Harris Journal: Eur Neuropsychopharmacol Date: 2016-04-12 Impact factor: 4.600
Authors: Yasmin Schmid; Florian Enzler; Peter Gasser; Eric Grouzmann; Katrin H Preller; Franz X Vollenweider; Rudolf Brenneisen; Felix Müller; Stefan Borgwardt; Matthias E Liechti Journal: Biol Psychiatry Date: 2014-11-29 Impact factor: 13.382
Authors: P Strajhar; Y Schmid; E Liakoni; P C Dolder; K M Rentsch; D V Kratschmar; A Odermatt; M E Liechti Journal: J Neuroendocrinol Date: 2016-03 Impact factor: 3.627
Authors: Patrick C Dolder; Yasmin Schmid; Felix Müller; Stefan Borgwardt; Matthias E Liechti Journal: Neuropsychopharmacology Date: 2016-06-01 Impact factor: 7.853
Authors: Patrick C Dolder; Yasmin Schmid; Manuel Haschke; Katharina M Rentsch; Matthias E Liechti Journal: Int J Neuropsychopharmacol Date: 2015-06-24 Impact factor: 5.176
Authors: Robin L Carhart-Harris; Suresh Muthukumaraswamy; Leor Roseman; Mendel Kaelen; Wouter Droog; Kevin Murphy; Enzo Tagliazucchi; Eduardo E Schenberg; Timothy Nest; Csaba Orban; Robert Leech; Luke T Williams; Tim M Williams; Mark Bolstridge; Ben Sessa; John McGonigle; Martin I Sereno; David Nichols; Peter J Hellyer; Peter Hobden; John Evans; Krish D Singh; Richard G Wise; H Valerie Curran; Amanda Feilding; David J Nutt Journal: Proc Natl Acad Sci U S A Date: 2016-04-11 Impact factor: 12.779
Authors: Felix Müller; Patrick C Dolder; André Schmidt; Matthias E Liechti; Stefan Borgwardt Journal: Neuroimage Clin Date: 2018-03-07 Impact factor: 4.881
Authors: Adam L Halberstadt; Muhammad Chatha; Adam K Klein; John D McCorvy; Markus R Meyer; Lea Wagmann; Alexander Stratford; Simon D Brandt Journal: Neuropharmacology Date: 2019-11-19 Impact factor: 5.273